Daptomycin intravenous - Xellia Pharmaceuticals

Drug Profile

Daptomycin intravenous - Xellia Pharmaceuticals

Latest Information Update: 27 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Xellia Pharmaceuticals
  • Class Antibacterials; Cyclic peptides; Lipopeptides; Peptide antibiotics
  • Mechanism of Action Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Registered Bacteraemia; Skin and soft tissue infections

Most Recent Events

  • 20 Oct 2017 Registered for Bacteraemia in USA (IV)
  • 20 Oct 2017 Registered for Skin and soft tissue infections in USA (IV)
  • 01 Aug 2017 Registered for Bacteraemia in United Kingdom, Italy, Spain, Germany, Germany, France, Ireland and Austria (IV) before August 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top